Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) will release its financial results for the half-year ended June 30, 2026 on Thursday, August 20, 2026. The Melbourne-based radiopharmaceutical company scheduled the disclosure to provide investors with timely updates on its commercial franchise and late-stage therapeutic pipeline progress during the first half of the year.

An investor webcast and conference call will be held immediately following the release at 9:00 a.m. AEST on August 20, 2026 (7:00 p.m. EDT on Wednesday, August 19, 2026). Participants can register for the webcast or teleconference via the link provided in the company’s official announcement. The event allows management to address questions regarding the financial performance and operational developments reported in the filing.

Reporting Timeline

The following table outlines the key dates for the Half-Year 2026 results announcement:

Business Context

Telix Pharmaceuticals is a commercial-stage global radiopharmaceutical company advancing targeted theranostics to improve outcomes for people with cancer. Theranostics pairs a precision diagnostic with a targeted therapy to both diagnose and treat disease. The company’s commercial franchise is anchored by its prostate cancer imaging portfolio, including Illuccix, which is commercially available in 22 countries including the U.S., and Gozellix, which is approved by the U.S. Food and Drug Administration (FDA).

The company’s late-stage therapeutic pipeline includes three investigational assets in pivotal-stage trials: TLX591-Tx in prostate cancer, TLX101-Tx in recurrent glioblastoma, and TLX250-Tx in kidney cancer. These assets are complemented by a deep pipeline of next-generation candidates. Telix is headquartered in Melbourne, Australia, with operations across North America, Europe, Latin America, and Asia-Pacific.

Regulatory Disclosures

The announcement has been authorized for release by Telix Pharmaceuticals Limited’s Company Secretary, Shomalin Naidoo. The company notes that the information contained in the announcement is not intended to be an offer for subscription, invitation, or recommendation with respect to securities of Telix Pharmaceuticals Limited in any jurisdiction, including the United States. Forward-looking statements included in the announcement involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from any future results expressed or implied.

Telix Pharmaceuticals Limited announced the publication of results from the ProstACT SELECT study in Cancers, a peer-reviewed journal. The Phase 1 study evaluated TLX591-Tx (lutetium-177 rosopatamab tetraxetan), a prostate-specific membrane antigen (PSMA) targeting radio antibody-drug conjugate therapy candidate. The publication confirms the utility of gallium-68 PSMA-PET imaging to select patients for TLX591-Tx therapy using a theranostic approach.

The study highlights TLX591-Tx’s differentiated clinical profile, characterized by an intensified dosing schedule, prolonged tumor retention, and low exocrine gland irradiation. In a heterogeneous population representative of a real-world setting, TLX591-Tx therapy in combination with standard of care demonstrated a manageable and predictable safety profile. Indicative efficacy was observed, with a median radiographic progression-free survival (rPFS) of 8.8 months reported in evaluable patients.

Key Findings from ProstACT SELECT

Nat Lenzo, MD, Nuclear Medicine Oncologist and Principal Investigator on the ProstACT SELECT study, commented on the results. "A key objective of ProstACT SELECT was to determine whether PSMA-PET imaging could reliably identify patients suitable for TLX591-Tx therapy, and the results clearly support this approach," Lenzo stated. The findings provide evidence that the PSMA-PET imaging agent and TLX591-Tx target the same disease sites, supporting the ongoing ProstACT Global trial for metastatic castration-resistant prostate cancer (mCRPC).

Ongoing Clinical Development

David N. Cade, MD, Group Chief Medical Officer at Telix, emphasized the significance of the publication. "The peer-reviewed results support our patient-selection strategy and demonstrate a differentiated pharmacologic profile characterized by durable tumor targeting, hepatobiliary clearance, and a manageable safety profile," Cade said. Telix is currently evaluating TLX591-Tx in the international multi-center Phase 3 ProstACT Global study for advanced metastatic prostate cancer.

The primary objectives of the ProstACT SELECT trial were to determine whole body biodistribution and organ radiation dosimetry and assess the safety and tolerability of TLX591-Tx in patients with advanced mCRPC. rPFS was a secondary study objective. TLX591-Tx has not received a marketing authorization in any jurisdiction.